At the same time, seven gene mutations (ARID1A, BCOR, MTOR, CREBBP, SPEN, NOTCH4, and TET1) were identified that were associated with the prognosis of GC patients receiving anti-PD-1/PD-L1 immunotherapy (He and Wang, 2020) which suggests that lncRNA may be used for risk stratification in GC patients by anti-PD-1/PD-L1 immunotherapy. The gene discussed is BCOR; the disease is gastric cancer.